| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$70 |
Vection Reports 1H FY26 Results
|
27 Feb 2026 9:36AM |
$0.026 |
$0.030 |
risen by
15.38%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Record revenue of $17.4 million, a 34% increase from the previous year.
- Gross profit doubled to $9.7 million with a 56% gross margin.
- First positive underlying EBITDA of $0.2 million.
- Defence sector established as a core growth engine with $27.7 million in orders.
- Secured a $22.3 million multi-year framework agreement in defence.
- Expanded AI and platform strategies with $4.6 million in AI contracts.
- Strengthened balance sheet with a $21 million capital raise.
- On track to complete acquisitions to expand APAC presence.
- Positive outlook for the second half of FY26 with strong financial momentum.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bathurst Resources Limited (BRL) ORDINARY FULLY PAID |
Materials |
$133 |
Half Year Results - December 2025
|
27 Feb 2026 9:36AM |
$0.625 |
$0.555 |
fallen by
11.20%
|
|
BRL - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY26 consolidated EBITDA was $16.2 million.
- Bathurst's cash balance stood at $155.6 million as of 31 December 2025.
- There was a significant decrease in export revenue due to reduced pricing.
- Domestic sales in the South Island declined due to customers shifting to alternative fuels.
- The 100% Bathurst owned Tenas Project continues to progress with expected production in FY29.
- The Buller Plateaux Continuation Project in New Zealand aims to extend mining operations for 15 years.
- Crown Mountain project's Bankable Feasibility Study showed a 200% improvement in pre-tax NPV10 to USD $942m.
- No dividends were declared during the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vection Technologies Ltd (VR1) ORDINARY FULLY PAID |
Information Technology |
$70 |
Half Yearly Report and Accounts
|
27 Feb 2026 9:36AM |
$0.026 |
$0.030 |
risen by
15.38%
|
|
VR1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 29.2% to $16.2 million.
- Net loss after tax amounted to $9.3 million.
- Positive underlying EBITDA reported at $0.2 million.
- Growth driven by Defence and Healthcare sectors.
- Cash and cash equivalents increased to $13.7 million.
- Focus on AI+XR ecosystem integration.
- Improved gross margin to 56% from 37%.
- Directors confident in continued operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Vitasora Health Limited (VHL) ORDINARY FULLY PAID |
Health Care |
$31 |
Appendix 4D and Half Year Financial Report
|
27 Feb 2026 9:35AM |
$0.025 |
$0.016 |
fallen by
36%
|
|
VHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Vitasora Health Limited reported strong revenue growth to $2.30 million.
- Total revenue including R&D tax incentives reached $2.85 million.
- Loss after tax for the period was $5.13 million, up from the previous year.
- Significant increase in issued capital and improved cash flow performance.
- Expansion of patient programs and technological upgrades implemented.
- Reimbursement reforms expected to benefit future financial results.
- Completed significant capital raising initiatives post-period end.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$155 |
Full Year 2025 Results Webinar Details
|
27 Feb 2026 9:35AM |
$0.875 |
$0.895 |
risen by
2.29%
|
|
| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$29 |
1H26 Results Presentation
|
27 Feb 2026 9:35AM |
$0.180 |
$0.123 |
fallen by
31.94%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased to A$29.0 million due to stronger Australian dollar and US funding issues
- Underlying EBITDA loss of A$5.9 million
- Significant contract signings in Europe, Latin America, and the US totaling A$11.9 million
- Introduction of FloodGateTM for floodplain management in Australia
- First corporate-funded project secured
- Anticipate improved US market conditions in H2 FY26
- Strong near-term pipeline with major projects expected to contribute to growth
- Policy-backed growth opportunities globally
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$155 |
Full Year 2025 Results Investor Presentation
|
27 Feb 2026 9:35AM |
$0.875 |
$0.895 |
risen by
2.29%
|
|
6KA - Price-sensitive ASX Announcement
Full Release
Key Points
- Sustained demand for 6KA’s powder driven by production parts usage.
- Strong customer demand in suppressor market for nickel and titanium powders.
- DLA program demonstrated successful upcycling of government scrap.
- Revenue growth in 2H25 accelerated by 37% HoH.
- Successful commissioning of the atomizer boosted nickel sales.
- Gross margin loss reduced by 80% HoH into 2H25.
- Introduced service revenue model for titanium SWARF processing.
- Secured $1.9M order from a US-based aluminum producer.
- Raised $40M through ASX listing in December 2025.
- Expansion plans include new UniMelt systems and increased capacity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Noxopharm Limited (NOX) ORDINARY FULLY PAID |
Health Care |
$23 |
R&D rebate strengthens cash position
|
27 Feb 2026 9:35AM |
$0.065 |
$0.075 |
risen by
15.38%
|
|
NOX - Price-sensitive ASX Announcement
Full Release
Key Points
- Noxopharm Limited received a $2.8 million R&D rebate.
- The rebate strengthens the company's cash position.
- Funds are under the Australian Government's R&D Tax Incentive scheme.
- Supports Sofra™ technology platform development.
- Focuses on continuing success in HERACLES clinical trial.
- Targets treatment for cutaneous lupus and other chronic diseases.
- The global market for cutaneous lupus is valued at over US$3.3 billion.
- Sofra technology could impact autoimmune and cancer treatment markets.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Austral Gold Limited (AGD) ORDINARY FULLY PAID |
Materials |
$94 |
Austral Gold Files Appendix 4E Preliminary Final 2025 Report
|
27 Feb 2026 9:35AM |
$0.210 |
$0.140 |
fallen by
33.33%
|
|
AGD - Price-sensitive ASX Announcement
Full Release
Key Points
- Net profit after tax for FY25 was US$14.7 million.
- Total FY25 production was 15,392 gold equivalent ounces (GEOs).
- Revenue from ordinary activities increased by 39.1% to US$51.17 million.
- Reopened Casposo Mine in Argentina contributed 4,283 GEOs.
- Production at Guanaco Mine Complex in Chile was 11,109 GEOs.
- Production guidance for 2026 is set at 27,000–33,000 GEOs.
- Average realised price was US$3,576 per GEO.
- Cash and cash equivalents increased to US$10.5 million.
- Financial debt remained at US$26.6 million.
- The company sold shares of Unico Silver for net proceeds of US$4.7 million.
- A private placement raised approximately US$5.9 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Latrobe Magnesium Limited (LMG) ORDINARY FULLY PAID |
Materials |
$56 |
Latrobe Magnesium Achieves Continuous MgO Production
|
27 Feb 2026 9:34AM |
$0.020 |
$0.018 |
fallen by
10%
|
|
LMG - Price-sensitive ASX Announcement
Full Release
Key Points
- Development of a magnesium metal Demonstration Plant in Victoria's Latrobe Valley.
- Utilizing a patented extraction process on industrial ash waste.
- First half of the plant achieved sustained magnesium oxide production.
- Full Demonstration Plant commissioning expected in second half of 2026.
- Planned Commercial Plant with 10,000 tonnes per annum capacity.
- International 'Mega' Plant in Sarawak, Malaysia for 100,000 tonnes annually.
- Commitment to recycling, reducing landfill, and low carbon emissions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$155 |
Appendix 4G and Corporate Governance Statement
|
27 Feb 2026 9:34AM |
$0.875 |
$0.895 |
risen by
2.29%
|
|
| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$29 |
1H26 Results Release
|
27 Feb 2026 9:34AM |
$0.180 |
$0.123 |
fallen by
31.94%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- H1 FY26 revenue of A$29.0m, down A$3.0m
- Underlying EBITDA loss of A$5.9m
- Record European contract signings of A$6.9m
- Strong Latin American contract momentum
- First corporate-funded contract in the US worth A$2.3m
- Potential A$30m in tender projects
- A$9.3m in new work contracted in H2 FY26
- Expecting a stronger second half of FY26
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Medallion Metals Limited (MM8) ORDINARY FULLY PAID |
Materials |
$330 |
Acquisition Completion
|
27 Feb 2026 9:34AM |
$0.425 |
$0.415 |
fallen by
2.35%
|
|
MM8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of the acquisition of Forrestania Nickel Operation from IGO Limited.
- Forrestania Nickel Operation to be renamed Forrestania Gold Project.
- Medallion assumes full statutory and operational responsibility for the asset.
- Acquisition provides control over critical processing infrastructure.
- Transaction supports Medallion's long-term gold processing and development strategies.
- Key approvals, funding, and transaction milestones achieved.
- Handover set for 27 February 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| St George Mining Limited (SGQ) ORDINARY FULLY PAID |
Materials |
$472 |
Trading Halt
|
27 Feb 2026 9:33AM |
$0.160 |
$0.120 |
fallen by
25%
|
|
SGQ - Price-sensitive ASX Announcement
Full Release
Key Points
- St George Mining Limited requested a trading halt on its securities.
- Trading halt is pending an announcement regarding a substantial increase to the Company's Mineral Resource Estimate at the Araxa Project.
- The trading halt will remain until the earlier of the announcement release or the commencement of normal trading on Tuesday, 3 March 2026.
- St George Mining is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$165 |
ACW successfully completes $16.8m Placement and SPP
|
27 Feb 2026 9:33AM |
$0.042 |
$0.046 |
risen by
9.52%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical successfully completed a $16.8 million capital raising.
- $4.8 million was raised via a share purchase plan (SPP).
- The capital raising included a $12.0 million placement.
- The SPP was offered at $0.042 per share.
- 114 million new shares will be issued to SPP participants.
- CEO Dr. Steven Gourlay and non-executive directors committed to purchasing additional shares.
- The funds will support the XanaMIA phase 2b/3 Alzheimer’s trial and other initiatives.
- The company expects to have a cash balance of $29.5 million by December 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Rubicon Water Limited (RWL) ORDINARY FULLY PAID |
Information Technology |
$29 |
1H26 Appendix 4D and Half Year Report
|
27 Feb 2026 9:33AM |
$0.180 |
$0.123 |
fallen by
31.94%
|
|
RWL - Price-sensitive ASX Announcement
Full Release
Key Points
- Rubicon Water Limited reported a net loss after tax of $6,390,000 for the six months ended 31 December 2025.
- Revenue for the first half of 2025 was $29,022,000, down from $32,018,000 in the same period of 2024.
- The most significant revenue decline occurred in the ANZ segment, primarily due to decreased hardware and spare parts sales.
- Underlying EBITDA was a loss of $5,854,000, compared to a loss of $1,694,000 in the previous year.
- Rubicon Water Limited did not declare or pay any dividends during the reporting period.
- Net tangible assets per ordinary security decreased from $0.27 in 2024 to $0.21 in 2025.
- Exchange rate fluctuations contributed to a $2.1 million negative impact year-on-year due to a stronger Australian dollar.
- The Asia segment is expected to recover in the second half of the year with increased project activity.
- The company has joint ventures, including Medha Rubicon Water Technologies Pvt Ltd, in which it holds a 50% ownership interest.
- No significant events occurred after the reporting date that would impact the financial statements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Neurizon Therapeutics Limited (NUZ) ORDINARY FULLY PAID |
Health Care |
$62 |
Application for quotation of securities - NUZ
|
27 Feb 2026 9:32AM |
$0.100 |
$0.083 |
fallen by
17%
|
|
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$57 |
Annual Report to shareholders
|
27 Feb 2026 9:32AM |
$0.036 |
$0.049 |
risen by
36.11%
|
|
| Alpha HPA Limited (A4N) ORDINARY FULLY PAID |
Materials |
$944 |
Application for quotation of securities - A4N
|
27 Feb 2026 9:32AM |
$0.650 |
$0.650 |
fallen by
0%
|
|
| Invion Limited (IVX) ORDINARY FULLY PAID |
Health Care |
$6 |
Appendix 4D and Half Year Financial Report
|
27 Feb 2026 9:32AM |
$0.081 |
$0.062 |
fallen by
23.46%
|
|
IVX - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss after income tax for the half-year: $3,565,836
- Total assets as of 31 December 2025: $8,088,461
- Net assets as of 31 December 2025: $5,706,180
- No dividends paid or declared during the period
- Convertible notes issued for additional funding
- Significant expenditure on research and development
- PhotosoftTM technology focus and potential Orphan Drug Designation
- R&D tax incentive loan facility secured
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$380 |
FY25 Appendix 4E Preliminary Final Report
|
27 Feb 2026 9:31AM |
$1.235 |
$1.290 |
risen by
4.45%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Profit After Tax increased by 20% to PGK 120.7 million.
- Revenue from ordinary activities rose by 13% to PGK 545.5 million.
- Net interest income increased by 20%.
- Foreign exchange income grew by 17%.
- Unfranked dividends declared at AUD 6.5 cents per share.
- Operating expenses increased by 4%.
- Cost-to-income ratio improved to 54.7%.
- Loans and advances to customers increased by 13%.
- Capital adequacy ratios remained strong at 17.1%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Anteris Technologies Ltd (AVR) CHESS DEPOSITARY INTERESTS 1:1 US PROHIBITED |
Health Care |
$127 |
2025 Financial Results and Corporate Update
|
27 Feb 2026 9:31AM |
$8.870 |
$8.150 |
fallen by
8.12%
|
|
AVR - Price-sensitive ASX Announcement
Full Release
Key Points
- Initiated global pivotal PARADIGM Trial.
- Favorable 30-day and 1-year outcomes for DurAVR® THV.
- First successful double DurAVR® implant.
- Strengthened operational infrastructure and manufacturing capabilities.
- ISO 13485 certification for DurAVR® THV production.
- Net operating cash outflows of US$77.8 million in 2025.
- R&D expenses totaled US$69.1 million.
- Secured US$320 million in capital raises, including Medtronic investment.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Platinum International Fund (Quoted Managed Hedge Fund) (PIXX) |
Financials |
$78 |
2026 Interim Financial Report
|
27 Feb 2026 9:31AM |
$5.050 |
$5.200 |
risen by
2.97%
|
|
| Associate Global Partners Limited (APL) ORDINARY FULLY PAID |
Financials |
$17 |
Investor Presentation February 2026
|
27 Feb 2026 9:30AM |
$0.180 |
$0.300 |
risen by
66.67%
|
|
APL - Price-sensitive ASX Announcement
Full Release
Key Points
- Positive net inflows recorded in H1 FY2026.
- FUM reached $1.42 billion by December 2025.
- WCM product suite contributed significantly to FUM growth.
- Partnership with Switzer Financial Group enhances direct business capabilities.
- Strategic focus on expanding manager partnerships and launching new products.
- Achieved operating profitability in H1 FY26.
- Revenue increased by 10.2% in H1 FY26.
- Net loss reduced by 92.3% in H1 FY26.
- Five consecutive quarters of positive operating cash flow achieved.
- Ongoing initiatives to diversify investor base and drive sustainable growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bass Oil Limited (BAS) ORDINARY FULLY PAID |
Energy |
$22 |
Operations Update - January 2026
|
27 Feb 2026 9:30AM |
$0.050 |
$0.059 |
risen by
18%
|
|
BAS - Price-sensitive ASX Announcement
Full Release
Key Points
- Total sales revenue for January was A$471,374 net to Bass.
- Daily oil production for the group averaged 237 bopd for the month.
- Total Cooper Basin monthly production was 2,746 barrels.
- Total Indonesian oil production was 4,596 barrels net to Bass.
- Vanessa acquisition was approved by the regulator.
- Bass secured $3.5 million grant funding for Kiwi gas field development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
